Premium
Etanercept for therapy‐resistant macrophage activation syndrome
Author(s) -
Makay Balahan,
Yılmaz Şebnem,
Türkyılmaz Zeynep,
Ünal Nurettin,
Ören Hale,
Ünsal Erbil
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21019
Subject(s) - etanercept , medicine , macrophage activation syndrome , tumor necrosis factor alpha , arthritis , complication , prednisolone , immunology , rheumatology
Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of childhood rheumatic diseases, especially systemic onset juvenile idiopathic arthritis (SoJIA). We report a 4‐year‐old girl with probable SoJIA who presented with MAS. She did not respond to pulse methyl prednisolone and Cyclosporine A (CsA). She also failed to respond to intravenous immunoglobulin (IVIG) therapy. Etanercept was started, based on the observation of increased serum levels of tumor necrosis factor‐alpha (TNF‐α) in patients with MAS. Her condition improved following etanercept, suggesting that etanercept might have a therapeutic role in resistant MAS. Pediatr Blood Cancer 2008;50:419–421. © 2006 Wiley‐Liss, Inc.